Haematologica (Sep 2014)

The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01

  • Ursula Creutzig,
  • Martin Zimmermann,
  • Michael N. Dworzak,
  • Brenda Gibson,
  • Rienk Tamminga,
  • Jonas Abrahamsson,
  • Shau-Yin Ha,
  • Henrik Hasle,
  • Alexey Maschan,
  • Yves Bertrand,
  • Guy Leverger,
  • Christine von Neuhoff,
  • Bassem Razzouk,
  • Carmelo Rizzari,
  • Petr Smisek,
  • Owen P. Smith,
  • Batia Stark,
  • Dirk Reinhardt,
  • Gertjan L. Kaspers

DOI
https://doi.org/10.3324/haematol.2014.104182
Journal volume & issue
Vol. 99, no. 9

Abstract

Read online

The prognostic significance of early response to treatment has not been reported in relapsed pediatric acute myeloid leukemia. In order to identify an early and easily applicable prognostic factor allowing subsequent treatment modifications, we assessed leukemic blast counts in the bone marrow by morphology on days 15 and 28 after first reinduction in 338 patients of the international Relapsed-AML2001/01 trial. Both day 15 and day 28 status was classified as good (≤20% leukemic blasts) in 77% of patients. The correlation between day 15 and 28 blast percentages was significant, but not strong (Spearman correlation coefficient = 0.49, P20% had 4-year probabilities of survival of 52%±3% versus 36%±10% versus 21%±9% versus 14%±4%, respectively, P